Arsenic trioxide: Impact on the growth and differentiation of cancer cells and possible use in cancer therapy;Trójtlenek arsenu: Wpływ na procesy wzrostu i różnicowania komórek nowotworowych oraz możliwe zastosowanie w terapii choroby nowotworowej

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 67, Issue , 2013, Pages 817-827

  Hoffman, Ewelina ^a   Mielicki, Wojciech P ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; Arsenic trioxide; Glutathione; Kinase JNK

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; ARSENIC TRIOXIDE; CASPASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; ORGANOARSENIC DERIVATIVE; OXIDE;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; DRUG EFFECT; DRUG RESISTANCE; HUMAN; METABOLISM; MITOCHONDRION; NEOPLASM; PATHOLOGY; PROMYELOCYTIC LEUKEMIA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARSENICALS; CASPASES; CELL DIFFERENTIATION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MAP KINASE KINASE 4; MITOCHONDRIA; NEOPLASMS; NF-KAPPA B; OXIDES;

EID: 84892606195     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1061640     Document Type: Article

References (91)

1. Akao Y., Yamada H., Nakagawa Y.: Arsenic-induced apoptosis in malignant cells in vitro. Leuk. Lymphoma, 2000;37:53-63
2. Akay C., Gazitt Y.: Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. Cell Cycle, 2003;2:358-368
3. Akay C., Thomas C. 3rd, Gazitt Y.: Arsenic trioxide and paclitaxel induce apoptosis by different mechanisms. Cell Cycle, 2004;3:324-334
4. Azad M. B., Chen Y., Gibson S. B.: Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid. Redox. Signal., 2009;11:777-790
5. Bernstam L., Nriagu J.: Molecular aspects of arsenic stress. J. Toxicol. Environ. Health B. Crit. Rev., 2000;3:293-322
6. Bhattacharjee H., Carbrey J., Rosen B. P., Mukhopadhyay R.: Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. Biochem. Biophys. Res. Commun., 2004;322:836-841
7. Boe S. O., Simonsen A.: Autophagic degradation of an oncoprotein. Autophagy, 2010;6:964-965
8. Bolt A. M., Douglas R. M., Klimecki W. T.: Arsenite exposure in human lymphoblastoid cell lines induces autophagy and coordinated induction of lysosomal genes. Toxicol. Lett., 2010;199:153-159
9. Cao Y., Yu S. L., Wang Y., Guo G. Y., Ding Q., An R. H.: MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24. Tumour Biol., 2011;32:179-188
10. Chen X., Zhang M., Liu L. X.: The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells. Oncol. Rep., 2009;22:73-80
11. Cheng B., Yang X., An L., Gao B., Liu X.: Arsenic trioxide-induced apoptosis of Hep-2 cell line through modulating intracellular glutathione (GSH) level. Auris. Nasus. Larynx., 2010;37:89-94
12. Curtin J. C., Dragnev K. H., Sekula D., Christie A. J., Dmitrovsky E., Spinella M. J.: Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimulation of p53 transactivation function. Oncogene, 2001;20:2559-2569
13. Dai J., Weinberg R. S., Waxman S., Jing Y.: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood, 1999;93:268-277
14. Davey J. C., Bodwell J. E., Gosse J. A., Hamilton J. W.: Arsenic as an endocrine disruptor: effects of arsenic on estrogen receptor-mediated gene expression in vivo and in cell culture. Toxicol. Sci., 2007;98:75-86
15. Davison K., Mann K. K., Miller W. H. Jr.: Arsenic trioxide: mechanisms of action. Semin. Hematol., 2002;39:3-7
16. Davison K., Mann K. K., Waxman S., Miller W. H. Jr.: JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood, 2004;103:3496-3502
17. Diaz Z., Mann K. K., Marcoux S., Kourelis M., Colombo M., Komarnitsky P. B., Miller W. H. Jr.: A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. Leukemia, 2008;22:1853-1863
18. Dmoszowska A., Górska M.: Arsenic trioxide, an old drug - a new face. Acta Haematologica Polonica, 2004;35:5-14
19. Doudican N. A., Bowling B., Orlow S. J.: Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism. Leuk. Res., 2010;34:229-234
20. Eguchi R., Fujimori Y., Takeda H., Tabata C., Ohta T., Kuribayashi K., Fukuoka K., Nakano T.: Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells. J. Cell Physiol., 2011;226:762-768
21. El-Metwally T. H., Pour P. M.: The retinoid induced pancreatic cancer redifferentiation-apoptosis sequence and the mitochondria: a suggested obligatory sequence of events. JOP, 2007;8:268-278
22. Falanga A., Marchetti M., Vignoli A., Balducci D.: Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin. Adv. Hematol. Oncol., 2003;1:673-678
23. Fox E., Razzouk B. I., Widemann B. C., Xiao S., O'Brien M., Goodspeed W., Reaman G. H., Blaney S. M., Murgo A. J., Balis F. M., Adamson P. C.: Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood, 2008;111:566-573
24. Gao S. M., Chen C., Wu J., Tan Y., Yu K., Xing C. Y., Ye A., Yin L., Jiang L.: Synergistic apoptosis induction in leukemic cells by miR-15a/16-1 and arsenic trioxide. Biochem. Biophys. Res. Commun., 2010;403:203-208
25. Ghaffari S. H., Bashash D., Dizaji M. Z., Ghavamzadeh A., Alimoghaddam K.: Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action. Tumour Biol., 2012;33:157-172
26. Guo W., Wang H., Zhao W., Zhu J., Ju B., Wang X.: Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells. Chin. Med. J., 2001;114:30-34
27. Han Y. H., Moon H. J., You B. R., Kim S. Z., Kim S. H., Park W. H.: Effects of arsenic trioxide on cell death, reactive oxygen species and glutathione levels in different cell types. Int. J. Mol. Med., 2010;25:121-128
28. Ho S. Y., Chen W. C., Chiu H. W., Lai C. S., Guo H. R., Wang Y. J.: Combination treatment with arsenic trioxide and irradiation enhances apoptotic effects in U937 cells through increased mitotic arrest and ROS generation. Chem. Biol. Interact., 2009;179:304-313
29. Hong S. H., Yang Z., Privalsky M. L.: Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia. Mol. Cell. Biol., 2001;21:7172-7182
30. Huang C., Ke Q., Costa M., Shi X.: Molecular mechanisms of arsenic carcinogenesis. Mol. Cell Biochem., 2004;255:57-66
31. Izdebska M., Grzanka A., Szczepanski M. A., Litwiniec A.: Wybrane mechanizmy terapeutycznego oddziaływania trójtlenku arsenu w leczeniu nowotworów. Postȩpy Hig. Med. Dośw., 2008;62:463-467
32. Jeanne M., Lallemand-Breitenbach V., Ferhi O., Koken M., Le Bras M., Duffort S., Peres L., Berthier C., Soilihi H., Raught B., de The H.: PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell, 2010;18:88-98
33. Jin H. O., Seo S. K., Woo S. H., Lee H. C., Kim E. S., Yoo D. H., Lee S. J., An S., Choe T. B., Kim J. I., Hong S. I., Rhee C. H., Park I. C.: A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun. NH2-terminal kinase-dependent Bcl-xL phosphorylation. Lung Cancer, 2008;61:317-327
34. Jin H. O., Yoon S. I., Seo S. K., Lee H. C., Woo S. H., Yoo D. H., Lee S. J., Choe T. B., An S., Kwon T. J., Kim J. I., Park M. J., Hong S. I., Park I. C., Rhee C. H.: Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem. Pharmacol., 2006;72:1228-1236
35. Kang Y. H., Lee S. J.: The role of p38 MAPK and JNK in Arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells. J. Cell Physiol., 2008;217:23-33
36. Karczmarek-Borowska B., Zmorzyński S., Filip A.: Biologiczna rola surwiwiny. Współczesna Onkologia, 2008;12:437-440
37. Kerbauy D. M., Lesnikov V., Abbasi N., Seal S., Scott B., Deeg H. J.: NF-κB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood, 2005;106:3917-3925
38. Kim H. R., Kim E. J., Yang S. H., Jeong E. T., Park C., Kim S. J., Youn M. J., So H. S., Park R.: Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction. Int. J. Oncol., 2006;28:1401-1408
39. Kim K. B., Bedikian A. Y., Camacho L. H., Papadopoulos N. E., McCullough C.: A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer, 2005;104:1687-1692
40. Kitamura K., Minami Y., Yamamoto K., Akao Y., Kiyoi H., Saito H., Naoe T.: Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia, 2000;14:1743-1750
41. Kwaan H. C., Wang J., Boggio L. N.: Abnormalities in hemostasis in acute promyelocytic leukemia. Hematol. Oncol., 2002;20:33-41
42. Lallemand-Breitenbach V., Jeanne M., Benhenda S., Nasr R., Lei M., Peres L., Zhou J., Zhu J., Raught B., de The H.: Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol., 2008;10:547-555
43. Lallemand-Breitenbach V., Zhu J., Chen Z., de The H.: Curing APL through PML/RARA degradation by As2O3. Trends Mol. Med., 2012;18:36-42
44. Leu L., Mohassel L.: Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. Am. J. Health Syst. Pharm., 2009;66:1913-1918
45. Leung J., Pang A., Yuen W. H., Kwong Y. L., Tse E. W.: Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood, 2007;109:740-746
46. Li X., Ding X., Adrian T. E.: Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells. Cancer Invest., 2004;22:389-400
47. Li Y., Zhu X., Gu J., Dong D., Yao J., Lin C., Huang K., Fei J.: Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci., 2010;101:948-954
48. Ling Y. H., Jiang J. D., Holland J. F., Perez-Soler R.: Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol. Pharmacol., 2002;62:529-538
49. Liu Q., Hilsenbeck S., Gazitt Y.: Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood, 2003;101:4078-4087
50. Liu Z., Shen J., Carbrey J. M., Mukhopadhyay R., Agre P., Rosen B. P.: Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc. Natl. Acad. Sci. USA, 2002;99:6053-6058
51. Ma Y., Wang J., Liu L., Zhu H., Chen X., Pan S., Sun X., Jiang H.: Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB. Cancer Lett., 2011;301:75-84
52. Mathas S., Lietz A., Janz M., Hinz M., Jundt F., Scheidereit C., Bommert K., Dorken B.: Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis. Blood, 2003;102:1028-1034
53. McNeely S. C., Belshoff A. C., Taylor B. F., Fan T. W., McCabe M. J. Jr., Pinhas A. R., States J. C.: Sensitivity to sodium arsenite in human melanoma cells depends upon susceptibility to arsenite-induced mitotic arrest. Toxicol. Appl. Pharmacol., 2008;229:252-261
54. Meng Q., Peng Z., Chen L., Si J., Dong Z., Xia Y.: Nuclear factor-κB modulates cellular glutathione and prevents oxidative stress in cancer cells. Cancer Lett., 2010;299:45-53
55. Meng X. Z., Zheng T. S., Chen X., Wang J. B., Zhang W. H., Pan S. H., Jiang H. C., Liu L. X.: microRNA expression alteration after arsenic trioxide treatment in HepG-2 cells. J. Gastroenterol. Hepatol., 2011;26:186-193
56. Miller W. H. Jr.: Molecular targets of arsenic trioxide in malignant cells. Oncologist, 2002;7, Suppl 1:14-19
57. Miller W. H. Jr., Schipper H. M., Lee J. S., Singer J., Waxman S.: Mechanisms of action of arsenic trioxide. Cancer Res., 2002;62:3893-3903
58. Morales A. A., Gutman D., Cejas P. J., Lee K. P., Boise L. H.: Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. J. Biol. Chem., 2009;284:12886-12895
59. Muller S., Miller W. H. Jr., Dejean A.: Trivalent antimonials induce degradation of the PML-RARα oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. Blood, 1998;92:4308-4316
60. Muscarella D. E., Bloom S. E.: Differential activation of the c-Jun. N-terminal kinase pathway in arsenite-induced apoptosis and sensitization of chemically resistant compared to susceptible B-lymphoma cell lines. Toxicol. Sci., 2002;68:82-92
61. Nasr R., de The H.: Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. Int. J. Hematol., 2010;91:742-747
62. Osaki M., Takeshita F., Ochiya T.: MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers, 2008;13:658-670
63. Perkins C., Kim C. N., Fang G., Bhalla K. N.: Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x (L). Blood, 2000;95:1014-1022
64. Powell B. L., Moser B., Stock W., Gallagher R. E., Willman C. L., Stone R. M., Rowe J. M., Coutre S., Feusner J. H., Gregory J., Couban S., Appelbaum F. R., Tallman M. S., Larson R. A.: Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood, 2010;116:3751-3757
65. Qu G. P., Xiu Q. Y., Li B., Liu Y. A., Zhang L. Z.: Arsenic trioxide inhibits the growth of human lung cancer cell lines via cell cycle arrest and induction of apoptosis at both normoxia and hypoxia. Toxicol. Ind. Health, 2009;25:505-515
66. Ren Y., Xie Y., Chai L., Wang S., Cheng M.: Autophagy modification augmented the treatment effects initiated by arsenic trioxide in NB4 cells. Med. Oncol., 2011;28:231-236
67. Ruan K., Fang X., Ouyang G.: MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett., 2009;285:116-126
68. Ruiz-Ramos R., Lopez-Carrillo L., Rios-Perez A. D., De Vizcaya-Ruiz A., Cebrian M. E.: Sodium arsenite induces ROS generation, DNA oxidative damage, HO-1 and c-Myc proteins, NF-kappaB activation and cell proliferation in human breast cancer MCF-7 cells. Mutat. Res., 2009;674:109-115
69. Sertel S., Tome M., Briehl M. M., Bauer J., Hock K., Plinkert P. K., Efferth T.: Factors determining sensitivity and resistance of tumor cells to arsenic trioxide. PLoS One, 2012;7:e35584
70. Shi H., Shi X., Liu K. J.: Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol Cell Biochem., 2004;255:67-78
71. Singer M., Trugnan G., Chelbi-Alix M. K.: Arsenic trioxide reduces 2, 4, 6-trinitrobenzene sulfonic acid-induced murine colitis via nuclear factor-κB down-regulation and caspase-3 activation. Innate. Immun., 2010;17:365-374
72. Stepien A., Izdebska M., Grzanka A.: The types of cell death. Postȩpy Hig. Med. Dośw., 2007;61:420-428
73. Tallman M. S., Altman J. K.: How I treat acute promyelocytic leukemia. Blood, 2009;114:5126-5135
74. Tarhini A. A., Kirkwood J. M., Tawbi H., Gooding W. E., Islam M. F., Agarwala S. S.: Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer, 2008;112:1131-1138
75. Tatham M. H., Geoffroy M. C., Shen L., Plechanovova A., Hattersley N., Jaffray E. G., Palvimo J. J., Hay R. T.: RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol., 2008;10:538-546
76. Verrax J., Pedrosa R. C., Beck R., Dejeans N., Taper H., Calderon P. B.: In situ modulation of oxidative stress: a novel and efficient strategy to kill cancer cells. Curr. Med. Chem., 2009;16:1821-1830
77. Wang X., Gao P., Long M., Lin F., Wei J. X., Ren J. H., Yan L., He T., Han Y., Zhang H. Z.: Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med. Oncol., 2010;28:1225-1254
78. Wang Z. Y., Chen Z.: Acute promyelocytic leukemia: from highly fatal to highly curable. Blood, 2008;111:2505-2515
79. Wojtczak L., Zablocki K.: Mitochondria in cell life, death and disease. Postȩpy Biochem., 2008;54:129-141
80. Wysocki R., Wisniewska E.: Molekularne podstawy działania arszeniku w komórkach białaczki promielocytowej. Postȩpy Biochem., 2002;48:121-130
81. Xiao Y. F., Liu S. X., Wu D. D., Chen X., Ren L. F.: Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer. World J. Gastroenterol., 2006;12:5780-5786
82. Xiao Y. F., Wu D. D., Liu S. X., Chen X., Ren L. F.: Effect of arsenic trioxide on vascular endothelial cell proliferation and expression of vascular endothelial growth factor receptors Flt-1 and KDR in gastric cancer in nude mice. World J. Gastroenterol., 2007;13:6498-6505
83. Yang C. H., Kuo M. L., Chen J. C., Chen Y. C.: Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br. J. Cancer, 1999;81:796-799
84. Ye J., Li A., Liu Q., Wang X., Zhou J.: Inhibition of mitogen-activated protein kinase kinase enhances apoptosis induced by arsenic trioxide in human breast cancer MCF-7 cells. Clin. Exp. Pharmacol. Physiol., 2005;32:1042-1048
85. Zhang T. D., Chen G. Q., Wang Z. G., Wang Z. Y., Chen S. J., Chen Z.: Arsenic trioxide, a therapeutic agent for APL. Oncogene, 2001;20:7146-7153
86. Zhang X., Yang F., Shim J. Y., Kirk K. L., Anderson D. E., Chen X.: Identification of arsenic-binding proteins in human breast cancer cells. Cancer Lett., 2007;255:95-106
87. Zhao W., Wang H., Wang X., Wu F., Guo W., Qu B., Shen Z., Wang Z.: Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia. Thromb. Res., 2001;102:197-204
88. Zhao W. L., Chen S. J., Shen Y., Xu L., Cai X., Chen G. Q., Shen Z. X., Chen Z., Wang Z. Y.: Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies. Leuk. Lymphoma, 2001;42:1265-1273
89. Zhou J., Shi J., Hou J., Cao F., Zhang Y., Rasmussen J. T., Heegaard C. W., Gilbert G. E.: Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia. J. Thromb. Haemost., 2010;8:773-782
90. Zhu J., Koken M. H., Quignon F., Chelbi-Alix M. K., Degos L., Wang Z. Y., Chen Z., de The H.: Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA, 1997;94:3978-3983
91. Zhu J., Okumura H., Ohtake S., Nakamura S., Nakao S.: Arsenic trioxide induces apoptosis in leukemia/lymphoma cell lines via the CD95/CD95L system. Oncol. Rep., 2003;10:705-709